Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 8/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.44 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | EEF2K | O00418 | 1/20 | 0.37 |
| ▸ | IDH2 | P48735 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | DCK | P27707 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2669388 | 0.96 | GABRG2 (0.46) | GABRG2GABRB3GABRA2PDE4AEEF2K | |
| SCHEMBL2655799 | 0.94 | GABRG2 (0.52) | GABRG2GABRB3GABRA2PDE4ANPY1R | |
| SCHEMBL2662215 | 0.94 | PDE4A (0.47) | GABRG2GABRB3GABRA2PDE4ANPY1R | |
| SCHEMBL2656082 | 0.92 | GABRG2 (0.46) | GABRG2GABRB3GABRA2PDE4ANPY1R | |
| SCHEMBL2661686 | 0.90 | GABRG2 (0.53) | GABRG2GABRB3GABRA2PDE4AEEF2K | |
| SCHEMBL4913381 | 0.89 | PDE4A (0.40) | GABRG2GABRB3GABRA2PDE4AEEF2K | |
| SCHEMBL2659925 | 0.88 | GABRG2 (0.46) | GABRG2GABRB3GABRA2PDE4ANPY1R | |
| SCHEMBL4921314 | 0.85 | GABRG2 (0.41) | GABRG2GABRB3GABRA2PDE4AEEF2K | |
| SCHEMBL2669536 | 0.85 | NPY1R (0.41) | GABRG2GABRB3GABRA2PDE4ANPY1R | |
| SCHEMBL2661842 | 0.84 | GABRG2 (0.42) | GABRG2GABRB3GABRA2PDE4ANPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | claimed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | claimed |
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | GABRG2 592/4885GABRB3 332/4885GABRA2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.